Mercury-Induced Membranous Nephropathy in a Young Emirati Woman: A Hidden Threat in Cosmetic Creams

Introduction: Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults. While many cases are idiopathic and associated with autoantibodies such as anti-PLA2R, others are secondary to drugs, infections, malignancy, or toxins. Mercury exposure, especially via unregulated skin-lightening creams, represents a rare but reversible trigger of secondary MN. Case Description: A 19-year-old previously healthy Emirati woman initially presented with fever and a generalized erythematous rash. Months later, she developed progressive lower limb edema and periorbital puffiness. Laboratory workup revealed nephrotic-range proteinuria (urine PCR 9 g/g), hypoalbuminemia (1.8 g/dL), and preserved renal function. Comprehensive autoimmune and infectious serologies, including ANA, ANCA, anti-dsDNA, ENA, and serum PLA2R antibodies, were negative. Renal biopsy showed features consistent with MN: granular capillary wall staining for IgG, C3, kappa, and lambda by immunofluorescence, and negative glomerular PLA2R staining—raising suspicion for a secondary cause Discussion: A detailed environmental history revealed daily use of unlabeled skin-lightening creams for 3–6 months prior to symptom onset. Toxicology confirmed mercury exposure with blood mercury level of 12 μg/L (ref ≤2.0) and urine mercury level of 93 μg/L (ref ≤1.0), supporting the diagnosis of mercury-induced MN. Treatment and Outcome: The patient discontinued the creams and received corticosteroids, rituximab (2 doses), cyclosporine, and ACE inhibitor therapy. Over four months, her proteinuria declined to 1.5 g/day, with improved serum albumin and reduction in blood mercury levels. Conclusion: This case highlights the importance of environmental exposure history in young patients with PLA2R-negative MN. Mercury-induced MN is an under-recognized but treatable condition. Early identification and removal of the offending agent can result in clinical remission. Greater awareness and regulation of mercury-containing cosmetic products are urgently needed to prevent similar cases

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2025-10-01
DOI
https://doi.org/10.1681/asn.2025d3n3zyx2
Primary Topic
Mercury impact and mitigation studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mercury-Induced Membranous Nephropathy in a Young Emirati Woman: A Hidden Threat in Cosmetic Creams

Journal of the American Society of Nephrology
Mercury impact and mitigation studies
article

Mercury-Induced Membranous Nephropathy in a Young Emirati Woman: A Hidden Threat in Cosmetic Creams

article en

Abstract

Introduction: Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults. While many cases are idiopathic and associated with autoantibodies such as anti-PLA2R, others are secondary to drugs, infections, malignancy, or toxins. Mercury exposure, especially via unregulated skin-lightening creams, represents a rare but reversible trigger of secondary MN. Case Description: A 19-year-old previously healthy Emirati woman initially presented with fever and a generalized erythematous rash. Months later, she developed progressive lower limb edema and periorbital puffiness. Laboratory workup revealed nephrotic-range proteinuria (urine PCR 9 g/g), hypoalbuminemia (1.8 g/dL), and preserved renal function. Comprehensive autoimmune and infectious serologies, including ANA, ANCA, anti-dsDNA, ENA, and serum PLA2R antibodies, were negative. Renal biopsy showed features consistent with MN: granular capillary wall staining for IgG, C3, kappa, and lambda by immunofluorescence, and negative glomerular PLA2R staining—raising suspicion for a secondary cause Discussion: A detailed environmental history revealed daily use of unlabeled skin-lightening creams for 3–6 months prior to symptom onset. Toxicology confirmed mercury exposure with blood mercury level of 12 μg/L (ref ≤2.0) and urine mercury level of 93 μg/L (ref ≤1.0), supporting the diagnosis of mercury-induced MN. Treatment and Outcome: The patient discontinued the creams and received corticosteroids, rituximab (2 doses), cyclosporine, and ACE inhibitor therapy. Over four months, her proteinuria declined to 1.5 g/day, with improved serum albumin and reduction in blood mercury levels. Conclusion: This case highlights the importance of environmental exposure history in young patients with PLA2R-negative MN. Mercury-induced MN is an under-recognized but treatable condition. Early identification and removal of the offending agent can result in clinical remission. Greater awareness and regulation of mercury-containing cosmetic products are urgently needed to prevent similar cases

Journal of the American Society of NephrologyVol. 36(10S)
Dubai Hospital (AE)
Openalex Percentile: Top 39%
Mercury impact and mitigation studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.